Physician profile
Michael L Watson
NPI 1316366677
$4,597.22
in general payments reported to CMS, 2019-2025
26 companies · $999 in 2025
The $999 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $144 · 2021: $278 · 2022: $453 · 2023: $964 · 2024: $1,111 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.70 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $571.92 | 2020-2025 | |
| Novo Nordisk INC | $542.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $483.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $252.23 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.62 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $167.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $163.55 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $158.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $158.87 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.90 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $80.91 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.05 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $68.66 | 2020-2025 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $56.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2023-2025 | |
| Dexcom, INC. | $47.70 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $46.29 | 2024-2025 | Voquezna |
| Medtronic, INC. | $44.56 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $31.33 | 2021-2025 | Keveyis |
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Exact Sciences Corporation | $17.15 | 2025 | Cologuard Collection Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.00 | 2025 | |
| Insulet Corporation | $15.24 | 2025 | Omnipod |
| Shire North American Group INC | $12.23 | 2019 | |
| Merck Sharp & Dohme LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.